{"filing":{"accession_number":"0001999480-26-000022","cik":"0001999480","ticker":"ANRO","company_name":"Alto Neuroscience, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"alto-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/alto-20260812.htm"},"events":[{"id":27214,"run_id":24787,"accession_number":"0001999480-26-000022","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Alto Neuroscience disclosed financial results for the fiscal quarter ended June 30, 2026 via a press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $27.6 million (versus $17.7 million in Q2 2025), R\u0026D expenses of $22.1 million, G\u0026A expenses of $7.0 million, and balance sheet data as of June 30, 2026. This is a standard quarterly earnings release with financial statements and operational highlights, meeting the definition of earnings_release under Item 2.02.","company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28638,"accession_number":"0001999480-26-000022","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Alto Neuroscience disclosed financial results for the fiscal quarter ended June 30, 2026 via a press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $27.6 million (versus $17.7 million in Q2 2025), R\u0026D expenses of $22.1 million, G\u0026A expenses of $7.0 million, and balance sheet data as of June 30, 2026. This is a standard quarterly earnings release with financial statements and operational highlights, meeting the definition of earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:18:53.639511+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28638,"accession_number":"0001999480-26-000022","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Alto Neuroscience disclosed financial results for the fiscal quarter ended June 30, 2026 via a press release furnished as Exhibit 99.1. The disclosure includes consolidated statements of operations showing Q2 2026 net loss of $27.6 million (versus $17.7 million in Q2 2025), R\u0026D expenses of $22.1 million, G\u0026A expenses of $7.0 million, and balance sheet data as of June 30, 2026. This is a standard quarterly earnings release with financial statements and operational highlights, meeting the definition of earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:18:53.639511+00:00","company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","filing_date":"2026-08-12"}]}